LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts

PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma

(2020) Nora Wuerdemann et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus

(2019) Claus Wittekindt et al.   Cancer Prevention Research

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation

(2019) Nishant Mehta et al.   Cell Reports

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints

(2018) Tao Shi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine.

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

(2018) M Oliva et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?

(2017) Paolo A. Ascierto et al.   Journal of Translational Medicine

T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer

(2017) Jian-Feng Liu et al.   Molecular Oncology

Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma

(2017) Zhi-Zhang Yang et al.   Oncotarget

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management

(2016) Jessica H. Maxwell et al.   Annual Review of Medicine

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

(2016) Yayi He et al.   CANCER SCIENCE

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Profile of Tumor-Specific CD8+T Cell Hypofunction in a Transplantable Murine Cancer Model

(2016) Katherine A. Waugh et al.   JOURNAL OF IMMUNOLOGY

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

(2016) Xavier Castellsagué et al.   JNCI-Journal of the National Cancer Institute

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

(2016) Yuta Kondo et al.   ORAL ONCOLOGY

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

(2016) Xavier Castellsagué et al.   JNCI-Journal of the National Cancer Institute

Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence

(2015) I. Tinhofer et al.   EUROPEAN JOURNAL OF CANCER

Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma

(2015) Chen Cai et al.   WORLD JOURNAL OF UROLOGY

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

(2015) Ruea-Yea Huang et al.   Oncotarget

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity

(2014) Dallas B. Flies et al.   JOURNAL OF CLINICAL INVESTIGATION

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

Characterization of Programmed Death-1 Homologue-1 (PD-1H) Expression and Function in Normal and HIV Infected Individuals

(2014) Preeti Bharaj et al.   PLoS One

VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy

(2014) J. L. Lines et al.   Cancer Immunology Research

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ectopic Expression of TIM-3 in Lung Cancers

(2012) Xuewei Zhuang et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Tim-3, a negative regulator of anti-tumor immunity

(2012) Ana Carrizosa Anderson   CURRENT OPINION IN IMMUNOLOGY

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

(2012) Fu-Jun Li et al.   IMMUNOLOGY LETTERS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

(2012) Lukas Baitsch et al.   PLoS One

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

(2011) D. B. Flies et al.   JOURNAL OF IMMUNOLOGY

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

(2010) Rosemarie H. DeKruyff et al.   JOURNAL OF IMMUNOLOGY

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

(2010) Margaret K. Callahan et al.   SEMINARS IN ONCOLOGY